查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1798907

全球HER2乳癌檢測市場

HER2 Breast Cancer Tests
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 268 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年全球 HER2乳癌檢測市場規模將達到 5.295 億美元

全球HER2乳癌檢測市場規模預計在2024年為3.944億美元，到2030年將達到5.295億美元，在2024-2030年的分析期內，複合年成長率為5.0%。免疫組織化學檢測是本報告分析的細分領域之一，預計其複合年成長率為4.0%，到分析期結束時將達到3.313億美元。螢光/顯色原位雜合反應檢測細分領域在分析期間的複合年成長率預計為6.8%。

美國市場規模估計為 1.074 億美元，中國市場預計複合年成長率為 7.8%

美國HER2乳癌檢測市場規模預計在 2024 年達到 1.074 億美元。作為世界第二大經濟體，中國預計到 2030 年市場規模將達到 1.041 億美元，在 2024-2030 年的分析期內，複合年成長率為 7.8%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為 2.5% 和 5.0%。在歐洲，預計德國的複合年成長率為 3.2%。

全球 HER2乳癌檢測市場 - 主要趨勢與促進因素摘要

為什麼 HER2乳癌檢測在現代腫瘤學中至關重要？

HER2（人類表皮生長因子受體2）乳癌檢測是一種診斷程序，用於確定乳癌組織中HER2基因的過度表現或擴增。這些檢測對於確定治療策略至關重要，因為HER2陽性的癌症通常生長得更快，對標靶治療的反應也不同。準確的識別有助於選擇合適的治療方法，例如曲妥珠單抗和Pertuzumab，特異性抑制HER2活性並改善生存結局。

檢測通常使用免疫組織化學 (IHC) 或原位雜合反應(ISH) 技術對切片檢查或手術組織樣本進行。近年來，先進的檢測方法、數位病理學解決方案和伴隨診斷技術應運而生，以提高診斷準確性。 HER2 檢測現已成為腫瘤中心乳癌診斷的常規組成部分，這促使對高品質、可靠診斷平台的需求日益成長。

哪些診斷創新影響了檢測的準確性和採用率？

技術進步提高了 HER2 檢測的靈敏度、可重複性和可解釋性。免疫組化 (IHC) 檢測也不斷發展，包括抗體增強、自動化染色系統和標準化評分演算法。雙探針原位雜合技術 (ISH) 檢測可在可疑病例中提供確認，並有助於解決臨界 HER2 表達問題。螢光雜交 (FISH) 和顯色原位雜合技術 (CISH) 被廣泛用於在細胞層面確認基因擴增。

新的平台正在整合數位成像、人工智慧輔助病理學和多重檢測功能，以增強診斷工作流程。一些 HER2 檢測正在開發中，作為更廣泛的基因組分析檢測的一部分，這些檢測可同時評估多種生物標記。與標靶藥物共同開發的伴隨診斷檢測也越來越受歡迎，尤其是在 HER2 標靶療法擴展到其他癌症類型（例如胃癌和大腸癌）的情況下。

哪些地方的測試量在增加？哪些設施在推動這項成長？

乳癌發生率的上升以及腫瘤學中個人化醫療的日益普及，推動了全球檢測量的增加。醫院、專科癌症中心和參考實驗室是主要的檢測場所。在高所得國家，HER2 檢測是乳癌篩檢的標準項目；而在中等收入地區，由於病理基礎設施和治療可近性的改善，人們對 HER2 檢測的興趣日益濃厚。

北美和歐洲是成熟的市場，擁有完善的診斷指南和報銷系統。亞太地區正經歷快速成長，這得益於人們對乳癌的認知不斷提高、標靶治療的可及性不斷擴大以及政府支持癌症診斷的舉措。官民合作關係和國家癌症篩檢計畫的發展進一步加速了檢測的普及。

是什麼推動了 HER2乳癌檢測市場的成長？

HER2乳癌檢測市場的成長受到多種因素的推動，包括全球乳癌發生率的上升、HER2標靶治療藥物的使用增加以及診斷準確性的持續提高。染色試劑、自動化系統和人工智慧病理學工具的進步正在提高HER2檢測的準確性和擴充性。

癌症醫院、病理實驗室以及新型 HER2 標靶藥物伴隨診斷的終端應用不斷擴展，正在提升市場的重要性。監管機構核准在乳癌以外的腫瘤類型中進行 HER2 檢測，以及多重生物標記檢測的日益普及，正在拓寬其應用範圍。隨著精準醫療在腫瘤治療中的重要性日益凸顯，對可靠、高通量 HER2 檢測解決方案的需求預計將穩定成長。

部分

檢測類型（免疫組織化學、螢光/顯色原位雜合反應）；最終用戶（醫院最終用戶、診斷實驗室最終用戶）

受訪公司範例

  • Abbott Laboratories
  • Abnova Corporation
  • Agilent Technologies
  • Bio-Genex Laboratories
  • Beckman Coulter（Danaher）
  • Becton, Dickinson and Company（BD）
  • EKF Diagnostics
  • Hologic, Inc.
  • Leica Biosystems（Danaher）
  • Meridian Bioscience
  • Olympus Corporation
  • Oxford Gene Technology（Sysmex）
  • QIAGEN NV
  • REVEAL Genomics SL
  • Roche Diagnostics（F. Hoffmann-La Roche）
  • Thermo Fisher Scientific
  • Veracyte, Inc.
  • NeoGenomics Laboratories, Inc.
  • Empire Genomics/Biocare Medical
  • Applied Spectral Imaging

人工智慧整合

我們正在利用有效的專家內容和人工智慧工具來改變市場和競爭情報。

Global 特定產業產業SLM 的典型規範，而是建立了一個從世界各地專家收集的內容庫，包括影片錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP38902

Global HER2 Breast Cancer Tests Market to Reach US$529.5 Million by 2030

The global market for HER2 Breast Cancer Tests estimated at US$394.4 Million in the year 2024, is expected to reach US$529.5 Million by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Immunohistochemistry Test, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$331.3 Million by the end of the analysis period. Growth in the Fluorescence / Chromogenic In-Situ Hybridization Test segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$107.4 Million While China is Forecast to Grow at 7.8% CAGR

The HER2 Breast Cancer Tests market in the U.S. is estimated at US$107.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$104.1 Million by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global HER2 Breast Cancer Tests Market - Key Trends & Drivers Summarized

Why Are HER2 Breast Cancer Tests Essential in Modern Oncology?

HER2 (Human Epidermal Growth Factor Receptor 2) breast cancer tests are diagnostic procedures used to determine the overexpression or amplification of the HER2 gene in breast cancer tissue. These tests are critical in guiding treatment decisions, as HER2-positive cancers typically grow faster and respond differently to targeted therapies. Accurate identification allows for the selection of therapies such as trastuzumab or pertuzumab, which specifically inhibit HER2 activity and improve survival outcomes.

Testing is typically performed using immunohistochemistry (IHC) or in situ hybridization (ISH) techniques on biopsy or surgical tissue samples. In recent years, advanced assays, digital pathology solutions, and companion diagnostics have emerged to improve diagnostic precision. HER2 testing is now a routine part of breast cancer diagnosis in oncology centers, contributing to the growing demand for high-quality and reliable diagnostic platforms.

What Diagnostic Innovations Are Influencing Test Accuracy and Adoption?

Technological advancements have improved HER2 test sensitivity, reproducibility, and interpretability. IHC tests have evolved with enhanced antibodies, automated staining systems, and standardized scoring algorithms. Dual-probe ISH tests provide confirmation in ambiguous cases, helping resolve borderline HER2 expressions. Fluorescence ISH (FISH) and chromogenic ISH (CISH) remain widely used for confirming gene amplification at the cellular level.

Emerging platforms are integrating digital imaging, AI-assisted pathology, and multiplex testing capabilities to enhance diagnostic workflows. Some HER2 assays are now being developed as part of broader genomic profiling tests that assess multiple biomarkers simultaneously. Companion diagnostic tests co-developed with targeted drugs are also gaining traction, especially as HER2-targeted treatments expand into other tumor types like gastric and colorectal cancers.

Where Is Testing Volume Increasing, and Which Institutions Are Driving Uptake?

Testing volumes are rising globally due to increasing breast cancer incidence and the growing adoption of personalized medicine in oncology. Hospitals, cancer specialty centers, and reference laboratories are key testing sites. In high-income countries, HER2 testing is a standard part of breast cancer workups, while in middle-income regions, uptake is increasing with improvements in pathology infrastructure and treatment access.

North America and Europe are mature markets with well-established diagnostic guidelines and reimbursement systems. Asia Pacific is witnessing rapid growth due to rising breast cancer awareness, expanding access to targeted therapies, and government initiatives supporting oncology diagnostics. The development of public-private partnerships and national cancer screening programs is further accelerating testing penetration.

What Is Driving Growth in the HER2 Breast Cancer Tests Market?

Growth in the HER2 breast cancer tests market is driven by several factors including rising global breast cancer incidence, increased use of HER2-targeted therapies, and ongoing improvements in diagnostic precision. Advances in staining reagents, automation systems, and AI-powered pathology tools are making HER2 testing more accurate and scalable.

End-use expansion in oncology hospitals, pathology labs, and companion diagnostics for new HER2-targeted drugs is boosting market relevance. Regulatory approvals for HER2 testing in tumor types beyond breast cancer and increased adoption of multiplex biomarker panels are broadening application scope. As precision medicine becomes central to oncology care, demand for reliable, high-throughput HER2 testing solutions is expected to grow steadily.

SCOPE OF STUDY:

The report analyzes the HER2 Breast Cancer Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Immunohistochemistry Test, Fluorescence / Chromogenic In-Situ Hybridization Test); End-User (Hospitals End-User, Diagnostic Laboratories End-User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

  • Abbott Laboratories
  • Abnova Corporation
  • Agilent Technologies
  • Bio-Genex Laboratories
  • Beckman Coulter (Danaher)
  • Becton, Dickinson and Company (BD)
  • EKF Diagnostics
  • Hologic, Inc.
  • Leica Biosystems (Danaher)
  • Meridian Bioscience
  • Olympus Corporation
  • Oxford Gene Technology (Sysmex)
  • QIAGEN N.V.
  • REVEAL Genomics S.L.
  • Roche Diagnostics (F. Hoffmann-La Roche)
  • Thermo Fisher Scientific
  • Veracyte, Inc.
  • NeoGenomics Laboratories, Inc.
  • Empire Genomics / Biocare Medical
  • Applied Spectral Imaging

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • HER2 Breast Cancer Tests - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Breast Cancer Drives Consistent Demand for HER2 Status Testing in Oncology Diagnostics
    • Increased Adoption of Targeted Therapy Approaches Strengthens Business Case for Routine HER2 Screening
    • Growing Use of HER2 Tests in Treatment Stratification Spurs Integration into First-Line Diagnostic Protocols
    • Expansion of Companion Diagnostics for HER2-Targeted Drugs Throws Spotlight on Precision Testing Technologies
    • Regulatory Approvals for HER2-Positive Therapies Boost Clinical Need for Accurate and Standardized HER2 Testing
    • Adoption of FISH, IHC, and Dual ISH Techniques Enables Multi-Modality Testing Options in Oncology Labs
    • Rising Healthcare Access and Diagnostic Infrastructure in Emerging Markets Enhances HER2 Test Availability
    • Growth in Breast Cancer Screening Programs Supports Early Detection and HER2-Based Prognostic Evaluation
    • Increasing Use of Biopsy and Cytology Samples in HER2 Testing Expands Test Adoption Across Specimen Types
    • Integration of HER2 Testing in Comprehensive Genomic Panels Propels Use in Broader Molecular Oncology Workflows
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World HER2 Breast Cancer Tests Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for HER2 Breast Cancer Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immunohistochemistry Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Immunohistochemistry Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Fluorescence / Chromogenic In-Situ Hybridization Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Fluorescence / Chromogenic In-Situ Hybridization Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Fluorescence / Chromogenic In-Situ Hybridization Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Laboratories End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostic Laboratories End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • JAPAN
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • CHINA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • EUROPE
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for HER2 Breast Cancer Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • FRANCE
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • GERMANY
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for HER2 Breast Cancer Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • INDIA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for HER2 Breast Cancer Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for HER2 Breast Cancer Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for HER2 Breast Cancer Tests by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030
  • AFRICA
    • HER2 Breast Cancer Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for HER2 Breast Cancer Tests by Test Type - Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for HER2 Breast Cancer Tests by Test Type - Percentage Breakdown of Value Sales for Immunohistochemistry Test and Fluorescence / Chromogenic In-Situ Hybridization Test for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for HER2 Breast Cancer Tests by End-user - Hospitals End-User and Diagnostic Laboratories End-User Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for HER2 Breast Cancer Tests by End-user - Percentage Breakdown of Value Sales for Hospitals End-User and Diagnostic Laboratories End-User for the Years 2014, 2025 & 2030

IV. COMPETITION